PMID- 33358379 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20211214 IS - 1879-1476 (Electronic) IS - 0385-8146 (Linking) VI - 48 IP - 4 DP - 2021 Aug TI - Risk factors and survival outcomes of laryngeal squamous cell carcinoma patients with lung metastasis: A population-based study. PG - 723-730 LID - S0385-8146(20)30308-4 [pii] LID - 10.1016/j.anl.2020.11.009 [doi] AB - OBJECTIVE: It remains elusive which factors may influence the morbidity and mortality of lung metastasis (LM) in Laryngeal Squamous Cell Carcinoma (LSCC) patients. The aim of the present study was to investigate factors influencing LM and the survival outcomes of LSCC patients with LM. METHODS: We identified 10,935 patients with LSCC from 2010 to 2014 using the Surveillance, Epidemiology and End Results database. Multivariate logistic regression analysis was used to determine the factors associated with the presence of LM. Multivariate cox regression analysis was used to identify covariates associated with increased all-cause mortality in patients with LM. RESULTS: Among 10,935 patients with LSCC, 232 (2.12%) patients had LM. The median survival time of patients with LM was 8 months, and 8.37% of patients survived after 3 years. Patients with age >/= 60 years old, unmarried status, supraglottis, overlapping lesion of larynx, subglottis, pathological grade III, T4 stage, N1 stage, N2 stage, N3 stage and bone, brain or liver metastases were more likely to have LM. Survival analysis showed that chemotherapy and radiotherapy suggested better survival of LSCC patients with LM while pathological grade IV was associated with an increased all-cause mortality. CONCLUSION: The incidence of LSCC patients with LM varied by age, married status, and tumor subtypes. LSCC patients with LM had poor survival, and only 8.37% of patients survived after 3 years. However, chemotherapy and radiotherapy were found as independent favorable prognostic factors for survival. CI - Copyright (c) 2020. Published by Elsevier B.V. FAU - Yang, Weiqiang AU - Yang W AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: 497450210@qq.com. FAU - Mei, Xueshuang AU - Mei X AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: xueshuang_mei@163.com. FAU - Zhou, Yaqi AU - Zhou Y AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: yaqizhou_1988@163.com. FAU - Su, Rongfei AU - Su R AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: 389831354@qq.com. FAU - Lei, Wenbin AU - Lei W AD - Otorhinolaryngology Hospital, Institute of Otolaryngology, Guangdong Provincial Key Laboratory, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. Electronic address: leiwb@mail.sysu.edu.cn. FAU - Zheng, Shixin AU - Zheng S AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: 710918971@qq.com. FAU - Zhu, Rufei AU - Zhu R AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: 13091478@qq.com. FAU - Guo, Lianrong AU - Guo L AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: lrguo@126.com. FAU - Tao, Yuan AU - Tao Y AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: taop19772000@126.com. FAU - Su, Yongjin AU - Su Y AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: 1436390379@qq.com. FAU - Li, Jianyu AU - Li J AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: jianyuliy@163.com. FAU - Ding, Chuchu AU - Ding C AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: 18823856233@163.com. FAU - Zou, Songfeng AU - Zou S AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: songfengzou@gmail.com. FAU - Li, Xiaoling AU - Li X AD - Community Health Service Management Center, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518033, China. Electronic address: lixiaoling131151@163.com. FAU - Hu, Hongyi AU - Hu H AD - Department of Otorhinolaryngology, Hearing and Balance Function Medical Engineering Laboratory, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: huhongyi2006@outlook.com. LA - eng PT - Journal Article DEP - 20201224 PL - Netherlands TA - Auris Nasus Larynx JT - Auris, nasus, larynx JID - 7708170 SB - IM MH - Age Distribution MH - Aged MH - Carcinoma, Squamous Cell/mortality/pathology/*secondary MH - China/epidemiology MH - Female MH - Humans MH - Incidence MH - Laryngeal Neoplasms/mortality/*pathology MH - Logistic Models MH - Lung Neoplasms/mortality/pathology/*secondary MH - Male MH - Marital Status MH - Middle Aged MH - Neoplasm Staging MH - Prognosis MH - Proportional Hazards Models MH - Risk Factors MH - SEER Program MH - Survival Analysis OTO - NOTNLM OT - Chemotherapy OT - Laryngeal squamous cell carcinoma OT - Lung metastasis OT - Prognosis OT - Radiotherapy COIS- Declaration of Competing Interest The authors declare that they have no competing interests. EDAT- 2020/12/29 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/12/28 10:34 PHST- 2020/03/28 00:00 [received] PHST- 2020/11/04 00:00 [revised] PHST- 2020/11/18 00:00 [accepted] PHST- 2020/12/29 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/12/28 10:34 [entrez] AID - S0385-8146(20)30308-4 [pii] AID - 10.1016/j.anl.2020.11.009 [doi] PST - ppublish SO - Auris Nasus Larynx. 2021 Aug;48(4):723-730. doi: 10.1016/j.anl.2020.11.009. Epub 2020 Dec 24.